Document Detail

Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study.
MedLine Citation:
PMID:  22583925     Owner:  NLM     Status:  PubMed-not-MEDLINE    
AIM:   Statins, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, are reported to be useful for the treatment of non-alcoholic steatohepatitis (NASH). Currently, there is no proven therapy for NASH. In this study, we assessed the efficacy of rosuvastatin in NASH patients with dyslipidemia.
METHODS:   Nineteen patients with biopsy-proven NASH with dyslipidemia who agreed to participate in this prospective study were enrolled. The patients were treated for 24 months with 2.5 mg/day rosuvastatin. Clinical and histological alterations were comparatively evaluated before and after treatment. Standard weight-loss counseling was continued during the treatment period. Follow-up liver biopsy was performed in nine patients.
RESULTS:   Twenty-six percent of patients had hyperlipoproteinemia type IIa and 74% had hyperlipoproteinemia type IIb at baseline. Body mass indices were not significantly changed during the treatment. The levels of transaminases were relatively low at the beginning, and were not significantly changed during the treatment. Lipid profiles were significantly improved by the treatment with rosuvastatin for 24 months. While non-alcoholic fatty liver disease activity score and fibrotic stage did not change significantly in all patients, they were improved in 33.3% and 33.3% individual patients, and stayed stable in 33.3% and 55.6%, respectively.
CONCLUSION:   NASH-related metabolic parameters improved with therapy including histology in some patients. However, one of nine patients had progression of fibrosis during the treatment. Our pilot study demonstrated the efficacy of rosuvastatin for the treatment of NASH with dyslipidemia, even if transaminases are not so elevated and controlled trials are needed in the future.
Takashi Nakahara; Hideyuki Hyogo; Yuki Kimura; Tomokazu Ishitobi; Koji Arihiro; Hiroshi Aikata; Shoichi Takahashi; Kazuaki Chayama
Related Documents :
1874025 - Balloon dilation treatment of phimosis in boys. report of 512 cases.
19495525 - Cost-effective central venous line for infants in the developing world.
10150985 - Mechanical dilatation rather than plaque removal as major mechanism of transluminal cor...
14644515 - The pathway study: results of a pilot feasibility study in patients suspected of having...
7237715 - Comparison of resection versus patch aortoplasty for repair of coarctation in infants a...
22405915 - Clinical outcome after suture anchor repair for complete traumatic rupture of the dista...
Publication Detail:
Type:  Journal Article     Date:  2012-05-14
Journal Detail:
Title:  Hepatology research : the official journal of the Japan Society of Hepatology     Volume:  42     ISSN:  1386-6346     ISO Abbreviation:  Hepatol. Res.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-25     Completed Date:  2013-01-04     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9711801     Medline TA:  Hepatol Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1065-72     Citation Subset:  -    
Copyright Information:
© 2012 The Japan Society of Hepatology.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Biomarker and Dietary Validation of a Canadian Food Frequency Questionnaire to Measure Eicosapentaen...
Next Document:  Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing i...